Compare CARS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | IRWD |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.9M | 713.8M |
| IPO Year | 2017 | 2009 |
| Metric | CARS | IRWD |
|---|---|---|
| Price | $11.38 | $4.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $16.00 | $7.67 |
| AVG Volume (30 Days) | 488.8K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | 0.33 | ★ 0.55 |
| Revenue | ★ $723,239,000.00 | $298,276,000.00 |
| Revenue This Year | $3.03 | $57.95 |
| Revenue Next Year | $2.57 | $4.39 |
| P/E Ratio | $35.55 | ★ $7.75 |
| Revenue Growth | 0.57 | ★ 8.88 |
| 52 Week Low | $7.40 | $1.05 |
| 52 Week High | $13.85 | $5.78 |
| Indicator | CARS | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 47.17 |
| Support Level | $10.65 | $3.89 |
| Resistance Level | $11.61 | $4.53 |
| Average True Range (ATR) | 0.41 | 0.18 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 6.82 | 22.11 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.